A native TCR recognizes a MAGE-A3 peptide expressed by major histocompatibility complex (MHC) molecules on tumor cells. After affinity enhancement by mutations to the α chain, the TCR now recognizes the tumor cell with enhanced affinity but also recognizes another peptide derived from titin expressed by beating cardiomyocytes that is not recognized by the native TCR.